Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Average Recommendation of “Buy” by Brokerages

Monopar Therapeutics Inc. (NASDAQ:MNPR) has been assigned a consensus rating of “Buy” from the thirteen ratings firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, ten have given a buy rating and two have given a strong buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $107.00.

A number of research analysts recently commented on MNPR shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Monopar Therapeutics in a research report on Thursday, January 22nd. Barclays set a $125.00 target price on shares of Monopar Therapeutics and gave the company an “overweight” rating in a research note on Monday, October 13th. Morgan Stanley began coverage on shares of Monopar Therapeutics in a research note on Friday, January 9th. They issued an “overweight” rating and a $115.00 price target on the stock. Leerink Partners assumed coverage on Monopar Therapeutics in a report on Monday, November 10th. They set an “outperform” rating and a $115.00 price objective for the company. Finally, Wall Street Zen downgraded Monopar Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th.

Monopar Therapeutics Trading Up 8.4%

NASDAQ:MNPR opened at $65.48 on Tuesday. The firm has a market capitalization of $437.60 million, a price-to-earnings ratio of -19.03 and a beta of 1.46. Monopar Therapeutics has a 1-year low of $26.06 and a 1-year high of $105.00. The business’s fifty day moving average price is $71.39 and its 200 day moving average price is $65.92.

Monopar Therapeutics (NASDAQ:MNPR) last released its earnings results on Thursday, November 13th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.02). Equities analysts forecast that Monopar Therapeutics will post -1.65 earnings per share for the current year.

Insider Activity at Monopar Therapeutics

In other news, CFO Quan Anh Vu purchased 1,500 shares of the stock in a transaction that occurred on Friday, December 26th. The stock was acquired at an average price of $69.95 per share, with a total value of $104,925.00. Following the purchase, the chief financial officer owned 1,500 shares in the company, valued at $104,925. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 20.50% of the company’s stock.

Institutional Trading of Monopar Therapeutics

A number of institutional investors have recently added to or reduced their stakes in MNPR. Russell Investments Group Ltd. bought a new stake in Monopar Therapeutics in the third quarter worth approximately $28,000. BNP Paribas Financial Markets lifted its stake in shares of Monopar Therapeutics by 100.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock valued at $57,000 after purchasing an additional 349 shares during the last quarter. Police & Firemen s Retirement System of New Jersey bought a new stake in Monopar Therapeutics in the second quarter worth $34,000. AlphaQuest LLC increased its position in Monopar Therapeutics by 46.8% during the second quarter. AlphaQuest LLC now owns 1,784 shares of the company’s stock worth $64,000 after buying an additional 569 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its position in Monopar Therapeutics by 1,821.0% during the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after buying an additional 1,821 shares during the last quarter. 1.83% of the stock is currently owned by institutional investors and hedge funds.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.